Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 17
Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]
Authors Barabássy Á, Sebe B, Acsai K, Laszlovszky I, Szatmári B, Earley WR, Németh G
Received 21 April 2021
Accepted for publication 21 April 2021
Published 17 May 2021 Volume 2021:17 Pages 1481—1482
Barabássy Á, Sebe B, Acsai K, et al. Neuropsychiatr Dis Treat. 2021;17:957–970.
The authors have advised that there are errors in the first row of Table 5 on page 963.
Cariprazine 4.5 mg column, the value “1 (0.0)” should read “1 (0.2)”. Cariprazine 6 mg column, “2 (0.0)” should read “2 (0.3)”. Total 1.5-6 mg/d column, “0” should read “3 (0.1)”.
The authors apologize for these errors.
© 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.